St. Jude Children’s Research Hospital has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a tyrosine-protein kinase Lck targeting moiety via a linker acting as Lck degradation inducers reported to be useful for the treatment of cancer and immunological disorders.